Modality
Fusion Protein
MOA
FcRni
Target
PARP
Pathway
Lipid Met
MS
Development Pipeline
Preclinical
~Feb 2017
→ ~May 2018
Phase 1
Aug 2018
→ Jun 2030
Phase 1Current
NCT06115893
288 pts·MS
2018-08→2030-06·Completed
288 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-06-174.2y awayPh2 Data· MS
Trial Timeline
Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3
P1/2
Complet…
Catalysts
Ph2 Data
2030-06-17 · 4.2y away
MS
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06115893 | Phase 1/2 | MS | Completed | 288 | LiverFat |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Miriosocimab | Pfizer | Phase 1 | PARP | |
| ABB-2476 | AbbVie | Phase 1/2 | USP1 | |
| NVO-2974 | Novo Nordisk | NDA/BLA | PARP | |
| Suracagene | GSK | Phase 3 | PRMT5 | |
| Semainavolisib | Gilead Sciences | Phase 2 | PARP | |
| REG-6699 | Regeneron | Phase 2/3 | TIM-3 | |
| REG-861 | Regeneron | Phase 2 | PARP | |
| Zanufutibatinib | Intra-Cellular | NDA/BLA | CD38 | |
| CRS-337 | CRISPR Therapeutics | Phase 2/3 | PARP | |
| Cevinaritide | Praxis Precision | Phase 3 | AuroraA |